Urology/Gynecology/G.I., Strategic Development

Celsion Corp. reported two important milestones in the development of its lead drug ThermoDox(R), and in its transformation to a company totally focused on the development and commercialization of oncology drugs. On January 18th, the FDA notified the company that its Special Protocol Assessment (SPA) submission for Phase III liver cancer had been agreed to.